Skip to main content
Signal8
Launch Terminal

Freenome, Inc. (FRNM)

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).

Sector: Services-Medical Laboratories

Industry: Medical - Diagnostics & Research

Freenome, Inc. logo

Freenome, Inc.

NASDAQ:FRNMHealthcare
-2.95%$12.48
AH$12.48+0.00%vs close
Mkt Cap$1.34B
Float49.59M
O/S107.45M
Vol
$ Vol
RVOL
Inst Own9.0%
SI9.0%
Earnings
Dilution
Freenome, Inc. logoNASDAQ:FRNM$12.48-2.95%
FormDescription
13G/A
Beneficial Ownership Report (Amended)
424B3
Prospectus
4
8-K
7.01,8.01,9.01
2
S-8
SEC Filing
2
4
Statement of Changes in Beneficial Ownership
13G
Beneficial Ownership Report
1
EFFECT
Notice of Effectiveness
424B3
Prospectus
5
S-1
Registration Statement
6
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report
8-K/A
2.01,9.01
7
13G/A
Beneficial Ownership Report (Amended)
1
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
EFFECT
Notice of Effectiveness
4
Statement of Changes in Beneficial Ownership
POS AM
Post-Effective Amendment
2
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership
3
Initial Statement of Beneficial Ownership

1-25 of 135

…